Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05206500 · ClinicalTrials.gov registry record · Phase 4
NextGen - Clinical Implication of Next Generation Sequencing
A Phase 4 study of Urinary Tract Infections, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05206500 is a Phase 4 study of Urinary Tract Infections that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 100 participants, below the 455-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05206500, a Phase 4 study of Urinary Tract Infections, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Recently more advanced techniques, including Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) are available to detect bacteria in urine based on bacterial genomes. Comparing to traditional culture, these techniques have more sensitivity and could potentially be of a great help in patients with Colony Count of less than 10,000 and more than zero.
Conditions Studied
Interventions
- DRUG Antibiotic
- DEVICE Next Gen
Study Locations (1)
North Carolina
- Wake Forest Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-05-17 |
| Est. Completion | 2028-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05206500
The ClinicalTrials.gov registry entry for NCT05206500 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 455-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (78% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Tract Infections appearing as the primary indexed condition, and to 2 interventions - of which Antibiotic is the first listed.
NCT05206500 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05206500 about?
NCT05206500 is a clinical study titled "NextGen - Clinical Implication of Next Generation Sequencing". Recently more advanced techniques, including Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) are available to detect bacteria in urine based on bacterial genomes. Comparing to traditional culture, these techniques have more sensitivity and could potentially be of a great help in...
What is the current status of trial NCT05206500?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2022-05-17. Estimated completion is 2028-12.
What conditions does trial NCT05206500 study?
This clinical trial studies the following conditions: Urinary Tract Infections.
What interventions are being tested in trial NCT05206500?
The interventions under investigation include: Antibiotic (DRUG), Next Gen (DEVICE).
Who is sponsoring clinical trial NCT05206500?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05206500 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Tract Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chlorhexidine Lavage for Recurrent Urinary Tract Infection
ACTIVE NOT RECRUITING · Phase 4
-
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
RECRUITING · Phase 1
-
Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting
RECRUITING · NA
-
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
RECRUITING · NA
-
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
RECRUITING
-
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.